By Shaun Brown
Staff writer

OXFORD - Facing a moribund trading environment, some of Germany's biggest biotech names hope to offer investors more liquidity by splitting their stocks. Evotec BioSystems AG (NMarkt:EVO) and Qiagen N.V. (NMarkt:QIA; QGENF) last week announced intentions to undertake share splits in the coming weeks, while MorphoSys AG (NMarkt:MOR) and MWG-Biotech AG (NMarkt:NWU) confirmed to Ebb & Flow that they too are about to announce share split proposals to shareholders.